Morgan Stanley Centogene N.V. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Centogene N.V. stock. As of the latest transaction made, Morgan Stanley holds 5,231 shares of CNTG stock, worth $1,987. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,231

Previous 8,031 34.86%

Holding current value

$1,987

Previous $9,000 66.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.65 - $1.25 $1,820 - $3,500	-2,800 Reduced 34.86%	5,231 $3,000
Q4 2023 Feb 13, 2024	SELL	$1.02 - $1.47 $10,404 - $14,994	-10,200 Reduced 55.95%	8,031 $9,000
Q3 2023 Nov 15, 2023	BUY	$1.0 - $1.64 $1,400 - $2,296	1,400 Added 8.32%	18,231 $19,000
Q2 2023 Aug 14, 2023	SELL	$0.63 - $1.63 $189 - $488	-300 Reduced 1.75%	16,831 $25,000
Q1 2023 May 15, 2023	BUY	$0.65 - $1.43 $809 - $1,780	1,245 Added 7.84%	17,131 $11,000

Q4 2022 Feb 14, 2023	SELL	$0.72 - $0.97 $1,395 - $1,879	-1,938 Reduced 10.87%	15,886 $14,000
Q3 2022 Nov 14, 2022	BUY	$1.21 - $2.78 $2,156 - $4,953	1,782 Added 11.11%	17,824 $20,000
Q2 2022 Oct 27, 2022	BUY	$2.06 - $4.25 $4,556 - $9,401	2,212 Added 15.99%	16,042 $38,000
Q2 2022 Aug 15, 2022	BUY	$2.06 - $4.25 $4,556 - $9,401	2,212 Added 15.99%	16,042 $38,000
Q1 2022 Oct 27, 2022	SELL	$3.3 - $5.44 $7,299 - $12,033	-2,212 Reduced 13.79%	13,830 $58,000
Q1 2022 May 13, 2022	SELL	$3.3 - $5.44 $2,042 - $3,367	-619 Reduced 4.28%	13,830 $58,000
Q4 2021 Feb 14, 2022	SELL	$4.56 - $10.56 $291 - $675	-64 Reduced 0.44%	14,449 $75,000
Q3 2021 Nov 15, 2021	BUY	$9.9 - $11.72 $143,678 - $170,092	14,513 New	14,513 $159,000

Others Institutions Holding CNTG

# of Institutions

Shares Held

2.14M

Call Options Held

Put Options Held

View Full List

About Centogene N.V.

Ticker CNTG
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 27,081,600
Market Cap $10.3M
Description
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare dise...

More about CNTG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account